The sphingosine-1 phosphate receptor modulator “fingolimod”, which has shown possible efficacy in neuropsychiatric lupus manifestations in the MRL/lpr lupus mouse model [23], might therapeutically interfere with the monocyte-mediated orchestration of immune responses in SLE. The gene discussed is S1PR1; the disease is systemic lupus erythematosus.